X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (2) 2
aged, 80 and over (2) 2
cancer (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
care and treatment (2) 2
chemotherapy (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - pathology (2) 2
male (2) 2
metastasis (2) 2
abridged index medicus (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - pathology (1) 1
adult (1) 1
advanced nsclc (1) 1
af-001jp (1) 1
aged patients (1) 1
analysis (1) 1
anaplastic lymphoma kinase (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - blood (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
audio frequencies (1) 1
bevacizumab (1) 1
bevacizumab - administration & dosage (1) 1
brain neoplasms - secondary (1) 1
cancer research (1) 1
carbazoles - adverse effects (1) 1
carbazoles - blood (1) 1
carbazoles - therapeutic use (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - secondary (1) 1
central nervous system (1) 1
ch5424802 (1) 1
complications and side effects (1) 1
cut-off (1) 1
data processing (1) 1
death (1) 1
drug dosages (1) 1
effectiveness (1) 1
elderly (1) 1
feasibility studies (1) 1
feasibility study (1) 1
follow-up studies (1) 1
funding (1) 1
genetics (1) 1
group dynamics (1) 1
health aspects (1) 1
inhibitors (1) 1
interactive systems (1) 1
internal medicine (1) 1
kaplan-meier estimate (1) 1
kinases (1) 1
lung cancer (1) 1
lung neoplasms - enzymology (1) 1
lymphoma (1) 1
lymphomas (1) 1
medical colleges (1) 1
medical services (1) 1
medicine, general & internal (1) 1
middle aged (1) 1
motivation (1) 1
mutation (1) 1
neoplasm grading (1) 1
neoplasm recurrence, local - drug therapy (1) 1
neoplasm recurrence, local - pathology (1) 1
neoplasm staging (1) 1
non-small cell lung cancer (1) 1
oncology (1) 1
patients (1) 1
pemetrexed (1) 1
pemetrexed - administration & dosage (1) 1
pharmaceutical industry (1) 1
pharmaceuticals (1) 1
piperidines - adverse effects (1) 1
piperidines - blood (1) 1
piperidines - therapeutic use (1) 1
product development (1) 1
prognosis (1) 1
protein kinase inhibitors - adverse effects (1) 1
protein kinase inhibitors - blood (1) 1
protein kinase inhibitors - therapeutic use (1) 1
protein-tyrosine kinase (1) 1
pyrazoles - adverse effects (1) 1
pyrazoles - blood (1) 1
pyrazoles - therapeutic use (1) 1
pyridines - adverse effects (1) 1
pyridines - blood (1) 1
pyridines - therapeutic use (1) 1
receptor protein-tyrosine kinases - antagonists & inhibitors (1) 1
receptor protein-tyrosine kinases - metabolism (1) 1
recruitment (1) 1
research (1) 1
research article (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.